- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03477240
Feasibility Study Of A Telephonic Questionnaire For Follow-Up Of Locally Advanced Cervical Cancer Patients
A Cross-Sectional Feasibility Study of a Telephonic Questionnaire By Research Nurses For Follow-Up Of Locally Advanced Cervical Cancer Patients With Complete Response To Treatment.
Visão geral do estudo
Status
Descrição detalhada
Our institution registers on an average 670 cases of cancer cervix in a year and almost 75% are treated with curative intent, therefore around 500 patients a year would be treated with curative intent. Assuming that 75% of patients registered in a year would be receiving treatment at our institute, 375 patients a year would be completing treatment, of whom the investigator expect 80-85% ,i.e 300 patients to have a complete response. The list of patients who have completed radio(chemotherapy) in 2015 &2016 can be obtained from the Radiation Oncology Department records. Patients identified for a follow up visit will be telephonically contacted between one and two weeks before the planned clinic visit and verbal telephonic consent taken prior to the nurse-led interview. This study should be able to accrue 300 patients in 6 months.
Patients of locally advanced cervical cancer or vault cancer who have been treated with radiotherapy with or without concurrent chemotherapy and have a clinical complete response at 3 months post treatment and are within the first 2 years post treatment completion will be eligible to participate in this study.
Screening: Patients will be screened from the list of patients treated in the radiotherapy department over the last 2 years (2015-2016), available from the Radiation Oncology Information System (ROIS). All patients with a diagnosis of cervical cancer or vault cancer will be screened using the hospital Electronic Medical Record (EMR) to check stage of disease, schedule of treatment received, response at 3 months post treatment and expected date of next follow up.
If patient fulfils all inclusion criteria, she will be called by the research nurse, approximately 1-2 weeks prior to her expected date of follow up, for a preliminary conversation and invited to participate in the study.
After verbal telephonic consent is obtained, she will be interviewed by the clinical research nurse using the format of the prepared proforma (Form A) regarding symptoms suggestive of disease recurrence as well as treatment induced toxicity. At the end of the interview, the research nurse records her impression of whether the patient has worrisome symptoms of disease or not and has symptoms of treatment toxicity or not for which she should visit the hospital.
When the patient reports to the OPD the next week for scheduled physical follow up, the nurse completes the consenting process by taking a short written informed consent. The examining physician then takes a complete history and in addition, performs a physical examination and any investigations he/she deems necessary. Following this he/she notes down final impression of disease status and toxicity which are taken as the gold standard (Form B). Each patient will be interviewed only once during their follow up schedule.
In addition at the physical visit, information regarding the acceptability of nurse-led telephonic follow-up to the patient and the financial impact of physical follow- up will be collected using a structured format (Form C).
Study participant drop-out/ Lost-to-follow up: Patients may withdraw their consent at any point during the telephonic interview or the subsequent follow up visit.
- A patient who does not attend the scheduled follow up visit within 1-2 weeks of the telephonic interview will be called a second time to remind her of the follow up appointment and enquire about reasons for non-attendance in the clinic, which will be recorded. If patient does not report to the clinic within the next 2 weeks, she will be considered to have dropped out from the study.
- Those patients in whom the interval between telephonic interview and the physician's assessment is more than 4 weeks, will be considered drop outs and follow up telephone call will go out to enquire about reasons for non-attendance in the clinic, which will be recorded.
Tipo de estudo
Inscrição (Antecipado)
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Cervical Cancer Stage Ib2, II and III (Squamous carcinoma or adenocarcinoma)
- Cancer of the vault
- Cancer of the cervix which inadvertently underwent hysterectomy (inadequate surgery)
- Treated with curative intent with radical radio(chemo)therapy or NACT followed by radical radio(chemo)therapy and completed all curative treatment.
- Within 2 years post completion of treatment
- Has complete clinical response at 3 months post treatment
- Informed consent
- Contactable by telephone
Exclusion Criteria:
- Patients with Stage III disease treated with palliative intent with once monthly radiotherapy
- Early stage cervical cancer patients who underwent Wertheims hysterectomy and who have completed adjuvant radiochemotherapy due to high-risk factors
- Metastatic cervical cancers
- Patients who are unable to comprehend the questions or dialogue over telephone by medical staff.
- Patients who seem unreliable for follow up
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Accuracy of nurse-led telephonic interview for disease recurrence
Prazo: 1 YEAR
|
To estimate the accuracy of nurse-led telephonic interview in identifying patients with symptoms suggestive of disease recurrence, in terms of sensitivity and specificity values
|
1 YEAR
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Accuracy of nurse-led telephonic interview for late toxicity of treatment
Prazo: 1 YEAR
|
To estimate the accuracy of nurse-led telephonic interview in identifying patients with symptoms suggestive of late toxicity of treatment
|
1 YEAR
|
|
Acceptability of a nurse-led telephonic surveillance program using structured format (Form C).
Prazo: 1 YEAR
|
To assess patients' acceptability of a nurse-led telephonic surveillance program (if found to be concordant with physical clinic visits)
|
1 YEAR
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Antecipado)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- TMH-1950
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Câncer cervical estágio IIIB
-
Tata Memorial HospitalMahidol University; Juntendo University; Gunma University; Chiang Mai University...RecrutamentoCâncer Cervical Estágio IIA FIGO 2018 | Câncer Cervical Estágio IIB FIGO 2018 | Câncer cervical estágio IIIA FIGO 2018 | Câncer cervical estágio IIIB FIGO 2018 | Câncer cervical estágio IVA FIGO 2018 | Câncer Cervical Estágio IB FIGO 2018Índia, Japão, Tailândia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)ConcluídoAdenocarcinoma Intestinal Delgado | Adenocarcinoma do Intestino Delgado Estágio III AJCC v8 | Estágio IIIA Adenocarcinoma Intestinal Delgado AJCC v8 | Estágio IIIB Adenocarcinoma Intestinal Delgado AJCC v8 | Estágio IV Adenocarcinoma Intestinal Delgado AJCC v8 | Ampola de Vater Adenocarcinoma | Estágio... e outras condiçõesEstados Unidos
-
Shanghai First Maternity and Infant HospitalAinda não está recrutandoCâncer cervical, estágio IIB | Câncer cervical estágio IIIB | Câncer cervical estágio IIIA | Câncer cervical, estágio IVA
-
National Cancer Institute (NCI)NRG OncologyConcluídoAdenocarcinoma Cervical | Carcinoma Adenoescamoso Cervical | Carcinoma Espinocelular Cervical | Câncer cervical estágio IB2 AJCC v8 | Câncer Cervical Estágio II AJCC v8 | Câncer cervical estágio IIA AJCC v8 | Câncer cervical estágio IIA1 AJCC v8 | Câncer cervical estágio IIA2 AJCC v8 | Câncer cervical... e outras condiçõesEstados Unidos
-
M.D. Anderson Cancer CenterRetiradoCâncer cervical estágio IB3 FIGO 2018 | Câncer Cervical Estágio II FIGO 2018 | Câncer Cervical Estágio IIA FIGO 2018 | Câncer Cervical Estágio IIA1 FIGO 2018 | Câncer Cervical Estágio IIA2 FIGO 2018 | Câncer Cervical Estágio IIB FIGO 2018 | Câncer cervical estágio III FIGO 2018 | Câncer cervical estágio... e outras condições
-
National Cancer Institute (NCI)ConcluídoAdenocarcinoma Cervical | Carcinoma Adenoescamoso Cervical | Carcinoma Espinocelular Cervical | Carcinoma Cervical Recorrente | Câncer do colo do útero estágio IVA | Câncer do colo do útero estágio IVB | Câncer Cervical Estágio IIIA | Câncer cervical estágio IIIBCanadá
-
GOG FoundationNational Cancer Institute (NCI)ConcluídoAdenocarcinoma Cervical | Carcinoma Adenoescamoso Cervical | Carcinoma Espinocelular Cervical Sem Outra Especificação | Câncer Cervical Estágio IIA AJCC v7 | Câncer cervical estágio IIB AJCC v6 e v7 | Câncer cervical estágio IIIB AJCC v6 e v7 | Câncer cervical estágio IVA AJCC v6 e v7 | Câncer cervical...Estados Unidos, Canadá, Arábia Saudita, China, Cingapura
-
National Cancer Institute (NCI)NRG OncologyConcluídoAdenocarcinoma Cervical | Carcinoma Adenoescamoso Cervical | Carcinoma Espinocelular Cervical Sem Outra Especificação | Câncer cervical estágio IB2 AJCC v6 e v7 | Câncer Cervical Estágio II AJCC v7 | Câncer Cervical Estágio IIA AJCC v7 | Câncer cervical estágio IIB AJCC v6 e v7 | Câncer cervical estágio... e outras condiçõesEstados Unidos
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)DesconhecidoAdenocarcinoma Cervical | Carcinoma Adenoescamoso Cervical | Carcinoma Espinocelular Cervical Sem Outra Especificação | Câncer Cervical Estágio IIA AJCC v7 | Câncer cervical estágio IIB AJCC v6 e v7 | Câncer cervical estágio IIIB AJCC v6 e v7 | Câncer cervical estágio IVA AJCC v6 e v7 | Câncer cervical... e outras condiçõesEstados Unidos
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Ativo, não recrutandoCarcinoma de células escamosas cervical localmente avançado, sem outra especificação | Câncer cervical estágio IB3 FIGO 2018 | Câncer Cervical Estágio II FIGO 2018 | Câncer Cervical Estágio IIA FIGO 2018 | Câncer Cervical Estágio IIA1 FIGO 2018 | Câncer Cervical Estágio IIA2 FIGO 2018 | Câncer Cervical... e outras condiçõesEstados Unidos